CClinicalTrials.gg
CompletedNCT07128901Updated Sep 23, 2026

Lower-Limb Exoskeleton Technology for Non-Ambulatory Individuals With Spinal Cord Injury

An interventional study of Ekso Indego Therapy and Wandercraft Atalante X in Spinal Cord Injuries, sponsored by Georgia Institute of Technology. Completed at 1 site in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-09-23.

Sponsored by Georgia Institute of Technology · Not applicable, Interventional, and Basic science

Phase
Not applicable
Study type
Interventional
Enrollment
6
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Study summary

The purpose of this study is to compare two types of wearable lower-extremity exoskeletons -a self-balancing device lower-extremity exoskeleton and a user-balancing device lower-extremity exoskeleton-to better understand their effects on the physiological responses to walking and the user experience in people with spinal cord injury.

Read the detailed description

Although Lower Limb Exoskeleton technology holds promise for improving mobility and independence in people with Spinal Cord Injury, limited research has examined the physiological and psychological effects of walking with self-balancing lower limb exoskeleton technology compared to systems that require user-operated assistive aids. Moreover, no studies to date have directly compared the short- and long-term outcomes of two lower limb exoskeleton technology types: (1) self-balancing and (2) user-balancing. To address this gap, this study will conduct a head-to-head comparison of self-balancing and user-balancing lower limb exoskeleton technology in individuals with motor-complete (ASIA Impairment Scale Classification [AIS] A/B) Spinal Cord Injury-a population that remains underrepresented in rehabilitation robotics research despite advances in the field.

Study participants will complete 5 walking sessions and 2 test sessions with two different exoskeleton devices in a randomized order. During each test session, data will be collected using motion sensors, portable metabolic monitors, and muscle sensors.

02

Conditions studied

  • Spinal Cord Injuries

Keywords

  • lower limb exoskeleton
03

In context

Spinal Cord Injuries

1,948 studies on the registry are indexed under Spinal Cord Injuries; 505 are open to participants now.

This study's enrollment of 6 is below the median of 24 across 1,566 interventional studies indexed under Spinal Cord Injuries.

Browse Spinal Cord Injuries studies →

Lead sponsor

Georgia Institute of Technology is the lead sponsor of 24 studies on the registry; 5 are open to participants now.

Of its 9 completed or terminated interventional studies of FDA-regulated products, 7 (78%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Subacute to chronic SCI (≥ 3mths post injury)
  • Motor-complete (ASIA Impairment Scale classification A/B)
  • Injury level T3-T12
  • Age 18-70 yrs
  • Height between 5'1" and 6'1"
  • Weight \<200 lbs (90kg)
  • Seated hip width \< 42cm
  • Standing tolerance > 15mins
  • Have sufficient upper limb strength to use a platform rolling walker, rolling walker, or forearm crutches
  • Currently medically cleared and enrolled in the Shepherd Center Beyond Therapy program
  • Medically cleared for weight-bearing activities
  • Able to follow directions to safely participate in assessments

Exclusion criteria

Exclusion Criteria:

  • Existing skin lesions or wounds
  • Hip or knee contracture > 10 degrees or ankle contracture > 5 degrees
  • Severe or uncontrolled spasticity
  • Non-healing fractures
  • Uncontrolled autonomic dysreflexia
  • Heart or peripheral vascular condition
  • Pregnancy
  • Active heterotopic ossification
  • Active deep vein thrombosis
  • Cognitive deficits that make it difficult for participants to follow verbal instructions or making it unsafe to participate in assessments.
  • Any reason the principal investigator feels the potential participant may not be safe to participate in the study
05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
6 participants (actual)

Study arms

  • Experimental
    Self-balancing lower limb exoskeleton

    Participants will use the self-balancing lower limb exoskeleton for 5 walking sessions and then complete a test session.

    Device: Wandercraft Atalante X

  • Experimental
    User-balancing lower limb exoskeleton

    Participants will use the user-balancing lower limb exoskeleton for 5 walking sessions and then complete a test session.

    Device: Ekso Indego Therapy

Interventions

  • DeviceEkso Indego Therapy

    User-balancing lower Limb exoskeleton

  • DeviceWandercraft Atalante X

    Self-balancing lower limb exoskeleton

06

What researchers measure

Primary outcomes

  1. 10 meter walk test (10MWT)

    This will be measured as the participant walks a distance of 10 meters at their self-selected (or comfortable) walking speed. Three 10-meter walk trials will be completed by each participant at each time point. The average of three 10MWT walking speeds will be analyzed and reported. This measure will be recorded in seconds and converted to meters/s with higher values indicating faster speed and lower values indicating slower speeds. Self-selected walking speed is highly correlated with functional ability and dependence.

    Time frame: 1 year

  2. 6 minute walk test (6MWT)

    This is a measurement of endurance and functional ability that assesses the participants ability to walk a distance (meters) over a time period of 6 minutes. It is measured in distance with greater distances indicating improved levels of endurance and functional ability.

    Time frame: 1 year

Secondary outcomes

  1. Neuromuscular activation of specified muscles

    Electromyography sensors will measure the magnitude of muscle activation for the torso throughout the gait cycle. The average magnitude will be computed by averaging the time-series data across gait cycles and computing the average magnitude for the average gait cycle.

    Time frame: 1 year

  2. Walking economy

    Walking economy is a measure of the energy cost of walking, quantified as the amount of oxygen consumed per kilogram of body weight per meter walked. It reflects the metabolic efficiency of gait, with lower values indicating more efficient walking. This measure will be obtained using the Cosmed K5 indirect calorimetry system during steady-state walking.

    Time frame: 1 year

  3. Rating of Perceived Exertion

    The Rating of Perceived Exertion is a subjective measure of exertion based on an individual's perception of effort and fatigue during physical activity. The scale ranges from 6 (no exertion) to 20 (maximal exertion).

    Time frame: 1 year

  4. Total hemoglobin concentration

    Total hemoglobin concentration refers to the amount of hemoglobin present in a given volume of blood. It is an indicator of muscle oxygenation dynamics. This measure will be obtained using continuous wave near-infrared spectroscopy.

    Time frame: 1 year

  5. User-experience survey

    A custom survey will be administered to assess participant opinion on exoskeleton comfort, ease of use, perceived effort and overall satisfaction.

    Time frame: 1 year

07

Study locations

1 site
  • The Shepherd Center
    Atlanta, Georgia 30332, United States
08

References and documents

Study documents

  • Informed consent form · Jan 27, 2026

Documents are hosted by the registry — open the source record to download them.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07128901
Lead sponsor
Georgia Institute of Technology
Collaborators
Shepherd Center, Atlanta GA
Responsible party
Maegan Tucker (Assistant Professor, Georgia Institute of Technology) — Principal investigator
First posted
Aug 19, 2025
Start date
Dec 10, 2025
Primary completion
May 19, 2026
Completion
May 19, 2026
Last update
Sep 23, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion